R V Lloyd

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma
    Ricardo V Lloyd
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Surg Pathol 28:1336-40. 2004
  2. ncbi Advances in pituitary pathology: use of novel techniques
    Ricardo V Lloyd
    Mayo Clinic and Mayo Foundation, Laboratory Medicine and Pathology, Rochester, MN 55905, USA
    Front Horm Res 32:146-74. 2004
  3. ncbi Myosin XVA expression in the pituitary and in other neuroendocrine tissues and tumors
    R V Lloyd
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Pathol 159:1375-82. 2001
  4. ncbi Molecular pathology of pituitary adenomas
    R V Lloyd
    Department of Laboratory Medicine and Pathology, Mayo Foundation, Rochester, MN 55905, USA
    J Neurooncol 54:111-9. 2001
  5. ncbi Pituitary hyperplasia in glycoprotein hormone alpha subunit-, p18(INK4C)-, and p27(kip-1)-null mice: analysis of proteins influencing p27(kip-1) ubiquitin degradation
    Ricardo V Lloyd
    Department of Laboratory Medicine and Pathology, MayoClinic, Rochester, Minnesota 55905, USA
    Am J Pathol 160:1171-9. 2002
  6. ncbi p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers
    R V Lloyd
    Department of Laboratory Medicine and Pathology, Mayo Foundation and Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Pathol 154:313-23. 1999
  7. ncbi Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries
    L Jin
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Pathol 151:509-19. 1997
  8. ncbi Aberrant p27kip1 expression in endocrine and other tumors
    R V Lloyd
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Pathol 150:401-7. 1997
  9. ncbi Analysis of beta-catenin mutations and alpha-, beta-, and gamma-catenin expression in normal and neoplastic human pituitary tissues
    V Tziortzioti
    Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA
    Endocr Pathol 12:125-36. 2001
  10. ncbi Expression of D-type cyclins in normal and neoplastic rat pituitary
    X Qian
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Endocrinology 139:2058-67. 1998

Detail Information

Publications92

  1. ncbi Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma
    Ricardo V Lloyd
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Surg Pathol 28:1336-40. 2004
    ..Since most cases with metastatic disease had obvious invasion, caution should be used in making a diagnosis of FVPCA in the absence of the major histopathologic features or clear-cut invasive growth...
  2. ncbi Advances in pituitary pathology: use of novel techniques
    Ricardo V Lloyd
    Mayo Clinic and Mayo Foundation, Laboratory Medicine and Pathology, Rochester, MN 55905, USA
    Front Horm Res 32:146-74. 2004
    ....
  3. ncbi Myosin XVA expression in the pituitary and in other neuroendocrine tissues and tumors
    R V Lloyd
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Pathol 159:1375-82. 2001
    ..These data suggest that in neuroendocrine cells myosin XVA may have a role in secretory granule movement and/or secretion...
  4. ncbi Molecular pathology of pituitary adenomas
    R V Lloyd
    Department of Laboratory Medicine and Pathology, Mayo Foundation, Rochester, MN 55905, USA
    J Neurooncol 54:111-9. 2001
    ..Finally, recent comparative genomic hybridization studies show that many more genes that are important in pituitary tumorigenesis and tumor progression have yet to be discovered...
  5. ncbi Pituitary hyperplasia in glycoprotein hormone alpha subunit-, p18(INK4C)-, and p27(kip-1)-null mice: analysis of proteins influencing p27(kip-1) ubiquitin degradation
    Ricardo V Lloyd
    Department of Laboratory Medicine and Pathology, MayoClinic, Rochester, Minnesota 55905, USA
    Am J Pathol 160:1171-9. 2002
    ....
  6. ncbi p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers
    R V Lloyd
    Department of Laboratory Medicine and Pathology, Mayo Foundation and Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Pathol 154:313-23. 1999
    ..We also review studies indicating the increasingly important roles of p27, other CDKIs, and cyclins in endocrine cell hyperplasia and tumor development...
  7. ncbi Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries
    L Jin
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Pathol 151:509-19. 1997
    ....
  8. ncbi Aberrant p27kip1 expression in endocrine and other tumors
    R V Lloyd
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Pathol 150:401-7. 1997
    ..Immunohistochemical analysis of p27 along with Ki-67 may be used to assess the biological behavior of various neoplasms, to classify hyperplastic and neoplastic tissues, and to study cell cycle regulation during tumor progression...
  9. ncbi Analysis of beta-catenin mutations and alpha-, beta-, and gamma-catenin expression in normal and neoplastic human pituitary tissues
    V Tziortzioti
    Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA
    Endocr Pathol 12:125-36. 2001
    ....
  10. ncbi Expression of D-type cyclins in normal and neoplastic rat pituitary
    X Qian
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Endocrinology 139:2058-67. 1998
    ..Growth factors, such as bFGF and demethylation increased D-type cyclin expression, whereas ectopic overexpression of cyclin D1 stimulates cell proliferation and increases apoptosis in GH3 pituitary tumor cells...
  11. ncbi Pituitary carcinoma: an ultrastructural study of eleven cases
    B W Scheithauer
    Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Ultrastruct Pathol 25:227-42. 2001
    ..Despite the diagnostic utility of electron microscopy in the assessment of these rare tumors, the distinction of pituitary carcinoma from pituitary adenoma cannot be firmly made on ultrastructural grounds alone...
  12. ncbi Leptin and leptin receptor mRNA are widely expressed in tumors of adipocytic differentiation
    A M Oliveira
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Mod Pathol 14:549-55. 2001
    ..These results show for the first time that leptin and OB-Rb mRNA are expressed in lipomas, hibernomas, and liposarcomas. The presence of leptin and its receptor may provide new insights into the pathobiology of these tumors...
  13. ncbi Analysis of homogeneous populations of anterior pituitary folliculostellate cells by laser capture microdissection and reverse transcription-polymerase chain reaction
    L Jin
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Endocrinology 142:1703-9. 2001
    ....
  14. ncbi Identification and consequences of galectin-3 expression in pituitary tumors
    A Righi
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Mol Cell Endocrinol 326:8-14. 2010
    ..Given its role in pituitary tumor cell proliferation and in apoptosis, galectin-3 may be a target for the treatment of aggressive pituitary tumors...
  15. ncbi Pituitary adenoma in Carney complex: an immunohistochemical, ultrastructural, and immunoelectron microscopic study
    O Kurtkaya-Yapicier
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ultrastruct Pathol 26:345-53. 2002
    ..The lack of morphologic similarity between the 2 adenomas indicatesthat pituitary tumors in patients with Carney complex may not exhibit the same phenotype...
  16. ncbi The pituitary in Turner syndrome
    B W Scheithauer
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Endocr Pathol 16:195-200. 2005
    ....
  17. ncbi The long form of the leptin receptor (OB-Rb) is widely expressed in the human brain
    B Burguera
    Endocrine Research Unit, Mayo Clinic, Rochester, Minn, USA
    Neuroendocrinology 71:187-95. 2000
    ..This OB-Rb isoform seems to be widely expressed in the human brain with highest levels in the cerebellum. Obesity and hyperleptinemia appears not to be associated with down-regulation of the OB-Rb in the human brain...
  18. ncbi The pituitary in klinefelter syndrome
    B W Scheithauer
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Endocr Pathol 16:133-8. 2005
    ..The testes are small, blood testosterone levels are low, and blood gonadotropin levels are elevated. Pituitary changes in patients with Klinefelter syndrome have not been evaluated in detail...
  19. ncbi Pituitary adenoma: a DNA flow cytometric study of 192 clinicopathologically characterized tumors
    T A Gaffey
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Neuropathol 24:56-63. 2005
    ..When compared to long-term follow-up, neither this parameter nor ploidy correlated with tumor size or invasiveness. Lastly, long-term follow-up showed ploidy to be an unreliable predictor of tumor persistence or recurrence...
  20. ncbi Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cell adenomas
    K H Ruebel
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Endocr Pathol 12:281-9. 2001
    ....
  21. ncbi Leptin and leptin receptor in anterior pituitary function
    R V Lloyd
    Department of Laboratory Medicine and Pathology, Mayo Foundation, Rochester, MN 55905, USA
    Pituitary 4:33-47. 2001
    ..These proteins are activated by tyrosine-phosphorylation in anterior pituitary cells. The various steps in pituitary leptin signal transduction remain to be elucidated...
  22. ncbi Pituitary blastoma: a unique embryonal tumor
    Bernd W Scheithauer
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street, SW Rochester, MN 55905, USA
    Pituitary 15:365-73. 2012
    ..Variable MGMT reactivity suggests an incomplete response to temozolomide therapy. Literature regarding similar morphologically complex, infantile, Cushing disease-associated lesions is briefly reviewed...
  23. ncbi In situ hybridization detection of calcitonin mRNA in routinely fixed, paraffin-embedded tissue sections: a comparison of different types of probes combined with tyramide signal amplification
    X Qian
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Appl Immunohistochem Mol Morphol 9:61-9. 2001
    ....
  24. ncbi In situ hybridization for the identification of yeastlike organisms in tissue section
    R T Hayden
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Diagn Mol Pathol 10:15-23. 2001
    ..Its primary strength lies in the ability to speciate organisms accurately that are too few or atypical to identify based solely on morphologic features...
  25. ncbi Noninsulinoma pancreatogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes
    F J Service
    Division of Endocrinology and Metabolism, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 84:1582-9. 1999
    ....
  26. ncbi Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience
    D Erickson
    Department of Endocrinology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Endocrinol (Oxf) 71:92-9. 2009
    ..The cytogenesis and pathobiology of silent subtype 3 adenomas is unsettled...
  27. ncbi Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites
    A M Oliveira
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Am J Surg Pathol 25:815-9. 2001
    ..These results indicate that TTF-1 is clinically useful in distinguishing metastatic pulmonary from metastatic WDNET of extrapulmonary origin...
  28. ncbi Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms
    L A Erickson
    Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, 200 First Street SW, Rochester, NY 55905, USA
    Endocr Pathol 12:429-35. 2001
    ....
  29. ncbi Direct detection of Legionella species from bronchoalveolar lavage and open lung biopsy specimens: comparison of LightCycler PCR, in situ hybridization, direct fluorescence antigen detection, and culture
    R T Hayden
    Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Microbiol 39:2618-26. 2001
    ..WS staining, Legionella genus LC-PCR, and L. pneumophila species-specific ISH were useful as rapid tests with lung tissue...
  30. ncbi Analysis of Hurthle cell neoplasms of the thyroid by interphase fluorescence in situ hybridization
    L A Erickson
    Departments of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Am J Surg Pathol 25:911-7. 2001
    ..Among Hurthle cell carcinomas in this study, chromosome losses were identified only from patients who died of disease. The loss of chromosome 22 may have prognostic value in Hurthle cell carcinoma of the thyroid...
  31. ncbi Detection of fusion gene transcripts in fresh-frozen and formalin-fixed paraffin-embedded tissue sections of soft-tissue sarcomas after laser capture microdissection and rt-PCR
    L Jin
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Diagn Mol Pathol 12:224-30. 2003
    ..These results also suggest that RT-PCR analysis for sarcoma fusion gene products can be successfully performed when only a few cells are available for analysis, although this is not recommended for routine clinical use...
  32. ncbi Aberrant DNA methylation of cyclin D2 and p27 genes in rodent pituitary tumor cell lines correlates with specific gene expression
    X Qian
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Endocr Pathol 11:85-96. 2000
    ..These data indicate a coordinately reduced expression of these two linked genes in most rodent pituitary tumor cell lines and suggest that methylation of cyclin D2 and p27 might occur in a "hot spot" in this gene-rich cluster...
  33. ncbi Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver
    P S Kamath
    Departments of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Liver Transpl 6:596-602. 2000
    ..In late stages of cirrhosis, ET-1 may not modulate resistance. We speculate that vascular resistance in late stages of cirrhosis probably results from distortion of hepatic architecture...
  34. ncbi Carcinoid tumors of the stomach: a clinical and radiographic study
    A J Binstock
    Department of Radiology, Mayo Clinic, 200 First St. S.W, Mayo E2-B, Rochester, MN 55905, USA
    AJR Am J Roentgenol 176:947-51. 2001
    ..Third, the radiologic appearance and management of these tumors depend on the clinical background of the patient...
  35. ncbi Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas
    Roger D Klein
    Mayo Clinic, Rochester, MN, USA
    Diagn Mol Pathol 17:94-100. 2008
    ..The disparate mutational spectra in malignant paragangliomas and pheochromocytomas may reflect differences in underlying tumor biology...
  36. ncbi Induction of GH, PRL, and TSH beta mRNA by transfection of Pit-1 in a human pituitary adenoma-derived cell line
    Shunsuke Miyai
    Department of Pathology, Tokai University School of Medicine, Bohseidai Isehara Campus, Kanagawa 259 1193, Japan
    Cell Tissue Res 322:269-77. 2005
    ....
  37. ncbi Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery
    Geoffrey J Service
    Department of Surgery, Mayo Clinic and Foundation, Rochester, MN, USA
    N Engl J Med 353:249-54. 2005
    ..Hypoglycemic symptoms diminished postoperatively. We speculate that hyperfunction of pancreatic islets did not lead to obesity but that beta-cell trophic factors may have increased as a result of gastric bypass...
  38. ncbi Prognostic indicators in pituitary tumors
    Agustinus Suhardja
    Department of Radiology, SUNY Downstate Medical Center, Brooklyn, NY 11203 2098, USA
    Endocr Pathol 16:1-9. 2005
    ..We predict that the immunohistochemical methods now in use for assessment of tumor behavior will be complemented and partly replaced by molecular genetic procedures in the future...
  39. ncbi RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors
    Nobuki Nakamura
    Department of Laboratory Medicine and Pathology, Mayo Clinic Medical College, Rochester, MN 55905, USA
    Lab Invest 85:1065-75. 2005
    ..BRAF mutation occurs later in thyroid tumor progression and is restricted mainly to PTC and anaplastic thyroid carcinoma...
  40. ncbi Effects of TGFbeta1 on gene expression in the HP75 human pituitary tumor cell line identified by gene expression profiling
    Katharina H Ruebel
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA
    Endocrine 33:62-76. 2008
    ..These findings highlight the diverse gene networks and pathways through which TGFbeta operates in its effects on pituitary tumor cells...
  41. ncbi Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas
    Bettina Papouchado
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mod Pathol 18:1329-35. 2005
    ....
  42. ncbi Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors
    Peter M Sadow
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Endocr Pathol 19:97-103. 2008
    ..These results show that stathmin is expressed at higher levels in more rapidly proliferating endocrine tumors. However, it is probably not useful as a stand-alone marker to determine malignancy in pheochromocytomas for individual tumors...
  43. ncbi Pituitary carcinoma: a clinicopathological review
    Bernd W Scheithauer
    Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55901, USA
    Neurosurgery 56:1066-74; discussion 1066-74. 2005
    ..Recent studies have only begun to shed light on the probable mechanisms of tumor initiation and progression. A review of the clinicopathological and molecular genetic characteristics of pituitary carcinomas is presented...
  44. ncbi Effects of DNA methylation on galectin-3 expression in pituitary tumors
    Katharina H Ruebel
    Department of Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Cancer Res 65:1136-40. 2005
    ..Because it is functionally involved in cancer progression and metastasis, Gal-3 may serve as a possible therapeutic target in the treatment of pituitary tumors...
  45. ncbi Laser capture microdissection for analysis of single cells
    Nobuki Nakamura
    Department of Laboratory Medicine and Pathology, Mayo Clinic Medical College, Rochester, MN, USA
    Methods Mol Med 132:11-8. 2007
    ..These methods show the utility of immuno-LCM as well as LCM combined with RT-PCR for cellular and molecular studies of gene expression...
  46. ncbi Galectin-3 Expression in Functioning and Silent ACTH-Producing Adenomas
    Long Jin
    Department of Pathology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Endocr Pathol 16:107-14. 2005
    ..The use of ACTH and Gal-3 immunostaining should help in the diagnosis of silent ACTH adenomas...
  47. ncbi DNA microarrays: recent developments and applications to the study of pituitary tissues
    Xiang Qian
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocrine 28:49-56. 2005
    ....
  48. ncbi Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach
    Marco Volante
    Department of Clinical and Biological Sciences at San Luigi Hospital, University of Turin, Turin, Italy
    Am J Surg Pathol 31:1256-64. 2007
    ..An algorithmic approach was devised for practical use in the diagnosis of this tumor...
  49. ncbi Pancreatic intraepithelial neoplasia in heterotopic pancreas: evidence for the progression model of pancreatic ductal adenocarcinoma
    Lizhi Zhang
    Department of Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 31:1191-5. 2007
    ..The presence of PanIN in heterotopic pancreas from patients with ductal adenocarcinoma supports the progression model...
  50. ncbi Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors
    He Yu Zhang
    Department of Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocrine 30:299-306. 2006
    ..The other six genes did not show significant differences. These results suggest that increased methylation of RASSF1A and CTNNB1 may play important roles in progression and metastasis of small bowel carcinoid tumors...
  51. ncbi Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas
    Lori A Erickson
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 109:1965-71. 2007
    ..A series of 16 cutaneous metastases were analyzed from well-differentiated thyroid carcinomas to learn more about the clinicopathologic features and BRAF(V600E) mutation status...
  52. ncbi Galectin-4 expression in carcinoid tumors
    Kandelaria M Rumilla
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Endocr Pathol 17:243-9. 2006
    ..These results show a differential distribution of Gal-4 in carcinoid tumors in different locations of the gastrointestinal tract and the lungs...
  53. ncbi Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma
    Nobuki Nakamura
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocr Pathol 17:213-23. 2006
    ..These results indicate that some individual antibodies or a panel of antibodies combined with histopathological analysis can be useful in separating follicular adenoma (FA) from follicular variant of papillary thyroid carcinoma (FVPTC)...
  54. ncbi Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression
    Katharina H Ruebel
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
    Endocrine 29:435-44. 2006
    ..These results indicate that the LGALS3, hASH1, ID2, and TLE-4 genes may have important roles in the development of pituitary carcinomas...
  55. ncbi BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid
    Long Jin
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street, SW. Rochester, MN 55905, USA
    Diagn Mol Pathol 15:136-43. 2006
    ..However, the allele-specific LC PCR with CYBR green 1 method is most rapid, easier to perform, and least expensive technique, and it can be readily performed in most molecular diagnostic laboratories...
  56. ncbi Pathobiology of pituitary adenomas and carcinomas
    Bernd W Scheithauer
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Neurosurgery 59:341-53; discussion 341-53. 2006
    ....
  57. ncbi Immunohistochemical expression of nestin in the non-tumorous hypophysis and in pituitary neoplasms
    Fabio Rotondo
    Department of Laboratory Medicine, University of Toronto, St Michael s Hospital, 30 Bond Street, Toronto, ON, Canada, M5B 1W8
    Acta Neuropathol 111:272-7. 2006
    ..The patchy expression of nestin in endothelial cells remains unexplained and its significance requires further studies...
  58. ncbi Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists
    George Kontogeorgos
    Department of Pathology, G Gennimatas Athens General Hospital, KOFKA Bldg, 1st Floor, 154 Messogion Avenue, 115 27, Athens, Greece
    Acta Neuropathol 111:46-52. 2006
    ..These novel findings represent characteristic features of short-term dopamine agonist treatment, which are not seen in long-term treatment...
  59. ncbi Peritumoral steatosis associated with insulinomas: appearance at imaging
    Thomas D Atwell
    Department of Radiology, Mayo Clinic College of Medicine, 200 1st St SW, Rochester, MN 55905, USA
    Abdom Imaging 33:571-4. 2008
    ..We report three patients with insulinoma tumors and distinct peritumoral steatosis, well demonstrated with several imaging modalities. This unique appearance can aid in pre-operative diagnosis and guide biopsy...
  60. ncbi Molecular diagnosis of Ewing's sarcoma/primitive neuroectodermal tumor in formalin-fixed paraffin-embedded tissues by RT-PCR and fluorescence in situ hybridization
    Xiang Qian
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Diagn Mol Pathol 14:23-8. 2005
    ....
  61. ncbi Expression of caveolin-1 and caveolin-2 in the human pituitary: an immunohistochemical study
    Fabio Rotondo
    Department of Laboratory Medicine and Pathobiology, St Michael s Hospital, University of Toronto, Toronto, ON, Canada
    Endocr Pathol 15:345-50. 2004
    ..Not every endothelial cell was immunoreactive for the two caveolins, suggesting that the functional status of endothelial cells is not the same within the adenomas, not even in the same capillary...
  62. ncbi Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. Report of two cases
    Federico Roncaroli
    Department of Oncology, Bellaria Hospital, Bologna, Italy
    J Neurosurg 99:402-8. 2003
    ..Further studies are needed to determine whether HER-2/neu plays a role in the pathogenesis of pituitary carcinoma...
  63. ncbi Cyclooxygenase-2 expression in human pituitary tumors
    Sergio Vidal
    Department of Laboratory Medicine and Pathobiology, St. Michaels Hospital, University of Toronto, Ontario, Canada
    Cancer 97:2814-21. 2003
    ..Phamacologic inhibition of COX-2 activity might suppress angiogenesis in pituitary tumors and may provide a novel approach for medical therapy...
  64. ncbi Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1
    Mary B Casey
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Endocr Pathol 14:55-60. 2003
    ..HBME-1 was uncommon in the nonneoplastic cases. These results indicate that HBME-1 may be useful in helping to distinguish papillary thyroid carcinoma from hyperplasia in diagnostically difficult cases...
  65. ncbi Chromogranin a processing in human pituitary adenomas and carcinomas: analysis with region-specific antibodies
    Long Jin
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Endocr Pathol 14:37-48. 2003
    ..This study also shows the utility of tissue microarrays in the analysis of a large group of tumors with regionspecific antisera...
  66. ncbi Differential expression of galectin-3 in pituitary tumors
    Dominik Riss
    Department of Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer Res 63:2251-5. 2003
    ..Inhibition of Gal-3 gene expression by RNA interference decreased HP75 cell proliferation and increased apoptosis. These results indicate that Gal-3 has an important role in pituitary cell proliferation and tumor progression...
  67. ncbi Pathology of pituitary tumors
    Naoko Sanno
    Department of Neurosurgery, Nippon Medical School, 1 7 1 Nagayama, Tama, Tokyo 206 8512, Japan
    Neurosurg Clin N Am 14:25-39, vi. 2003
    ..In the second part, the classification of pituitary tumors is discussed, followed by the immunohistochemical and electron microscopic findings of pituitary adenomas and pituitary carcinomas...
  68. ncbi Galectin-3 expression in hyalinizing trabecular tumors of the thyroid gland
    Robyn L Gaffney
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Surg Pathol 27:494-8. 2003
    ..Our study suggests that the variable pattern of galectin-3 expression may reflect a difference in biologic behavior between HTT and papillary thyroid carcinoma...
  69. ncbi Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma
    Sanjay Kakar
    Department of Pathology, Mayo Clinic, Rochester, MN
    Am J Clin Pathol 119:361-6. 2003
    ..Cholangiocarcinoma and carcinomas from most other sites are negative for Hep Par 1. Hep Par 1 immunoreactivity shows high correlation with albumin ISH; their combined use for diagnosis of HCC had a sensitivity of 100% in this population...
  70. ncbi Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior
    Sergio Vidal
    Department of Anatomy, Laboratory of Histology, University of Santiago de Compostela Lugo, Spain
    Mod Pathol 15:1205-12. 2002
    ....
  71. ncbi Parathyroid carcinomas: can clinical outcomes for parathyroid carcinomas be determined by histologic evaluation alone?
    Kaori Kameyama
    Division of Diagnostic Pathology, Keio University School of Medicine, Shinjuku ku, Tokyo, Japan
    Endocr Pathol 13:135-9. 2002
    ..Kameyama, and discussed by Drs. Ronald DeLellis, Ricardo Lloyd, and Kennichi Kakudo. In this article, we summarize their diagnoses and comments...
  72. ncbi Localization of myosin XVA in endocrine tumors of gut and pancreas
    Stefano La Rosa
    Department of Pathology, Ospedale di Circolo, Varese, Italy
    Endocr Pathol 13:29-37. 2002
    ..Although the role of this protein in endocrine cells is unknown, previous studies suggest that it may have a role in secretory granule movement and/or hormone secretion...
  73. ncbi Expression and distribution of vascular endothelial growth factor receptor Flk-1 in the rat pituitary
    Sergio Vidal
    Department of Anatomy, Laboratory of Histology, University of Santiago de Compostela Lugo, 27002 Lugo, Spain
    J Histochem Cytochem 50:533-40. 2002
    ..The present study demonstrates that pituitary cells are not only sources of VEGF but also targets of this multifunctional substance, supporting the concept that VEGF functions as an autocrine/paracrine factor in the pituitary...
  74. ncbi Oxyphil parathyroid carcinomas: a clinicopathologic and immunohistochemical study of 10 cases
    Lori A Erickson
    Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Surg Pathol 26:344-9. 2002
    ..These findings also indicate that the same histopathologic features should be used to diagnose oxyphil and chief cell parathyroid carcinomas...
  75. ncbi Angiogenesis in patients with craniopharyngiomas: correlation with treatment and outcome
    Sergio Vidal
    Department of Laboratory Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
    Cancer 94:738-45. 2002
    ..VEGFR-2 may act as a key modulator of VEGF activity in endothelial cells and nonendothelial cells, indicating that VEGF plays an important role in the behavior of craniopharyngiomas...
  76. ncbi Crooke's cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma
    David H George
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester MN 55905, USA
    Am J Surg Pathol 27:1330-6. 2003
    ..Morbidity and mortality rates are substantial. CCAs represent a distinct entity that should be separated from corticotroph adenomas without Crooke's hyaline change...
  77. ncbi Merkel cell carcinomas: expression of S-phase kinase-associated protein 2 (Skp2), p27, and proliferation markers
    Lori A Erickson
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Endocr Pathol 14:221-29. 2003
    ....
  78. ncbi Cdx2 as a marker for neuroendocrine tumors of unknown primary sites
    Lori A Erickson
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocr Pathol 15:247-52. 2004
    ..These results indicate that Cdx2 can be very useful in recognizing metastatic neuroendocrine carcinomas of unknown primary sites, especially when they are derived from the small intestine...
  79. ncbi Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth
    Sabine Kajita
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mod Pathol 18:221-7. 2005
    ....
  80. ncbi Cystic adrenal neoplasms
    Lori A Erickson
    Department of Laboratory Medicine and Pathology Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 101:1537-44. 2004
    ..Cystic lesions of the adrenal gland are uncommon and demonstrate a spectrum of histologic changes and may vary from pseudocysts to malignant cystic neoplasms...
  81. ncbi Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions
    Mary B Casey
    The Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Endocr Pathol 15:107-16. 2004
    ..However, the expression of both COX-2 and TBXAS by thyroid tissue may provide insight into the role of these enzymes in progression from benign to malignant thyroid tumors...
  82. ncbi Practical markers used in the diagnosis of endocrine tumors
    Lori A Erickson
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Adv Anat Pathol 11:175-89. 2004
    ..This article reviews the common markers used to characterize endocrine tumors and to recognize tumors involved in the differential diagnosis of specific lesions...
  83. ncbi Analysis of parathyroid neoplasms by interphase fluorescence in situ hybridization
    Lori A Erickson
    Department of Laboratory Medicine and Pathology, Anatomic Pathology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Surg Pathol 28:578-84. 2004
    ..These results indicate that gain of chromosome 11 is associated with more aggressive biologic behavior in parathyroid neoplasms...
  84. ncbi Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas
    Onder Onguru
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, MN 55905, USA
    Mod Pathol 17:772-80. 2004
    ..These results indicate that activated epidermal growth factor receptor is expressed in pituitary adenomas and carcinomas. Higher levels in pituitary carcinomas suggest a role in pituitary tumor progression...
  85. ncbi Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas
    Onder Onguru
    Department of Pathology, Gulhane Military Medical Academy, Ankara, Turkey
    Endocr Pathol 15:17-27. 2004
    ..In summary, TBXAS appears to be one of the up-regulated downstream enzymes of Cox metabolism in pituitary tumors. Both Cox-2 and TBXAS may play an important role in pituitary tumor development and progression...
  86. ncbi Practical markers used in the diagnosis of neuroendocrine tumors
    Ricardo V Lloyd
    Mayo Clinic, Department of Laboratory Medicine and Pathology, 200 First Street SW, Rochester, MN 55905, USA
    Endocr Pathol 14:293-301. 2003
    ..2 to avoid false-negative results in the workup of some neuroendocrine tumors is emphasized. Finally, the use of in situ hybridization in diagnostic pathology is briefly summarized...
  87. ncbi Localization of inhibins and activins in normal endocrine cells and endocrine tumors of the gut and pancreas: an immunohistochemical and in situ hybridization study
    Stefano La Rosa
    Department of Pathology, Ospedale di Circolo
    J Histochem Cytochem 52:217-25. 2004
    ....
  88. ncbi Regulation of cell growth and expression of 7B2, PC2, and PC1/3 by TGFbeta 1 and sodium butyrate in a human pituitary cell line (HP75)
    Ikuo Kobayashi
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55901, USA
    Endocrine 22:285-92. 2003
    ..Our results also indicate that inhibition of pituitary cell proliferation is associated with increased expression of 7B2 mRNA...
  89. ncbi Immunohistochemical localization of amylin in human pancreas, thyroid, pituitary and their tumors
    Fabio Rotondo
    Department of Laboratory Medicine and Pathobiology, St Michael s Hospital, University of Toronto, Toronto, Canada
    Acta Histochem 105:303-7. 2003
    ..It can be concluded that amylin is not a satisfactory immunohistochemical marker to identify pancreatic islet tumors, medullary thyroid carcinomas and pituitary adenomas...
  90. ncbi Parathyroid carcinoma: is there a role for adjuvant radiation therapy?
    Nathan D Munson
    Division of Radiation Oncology, Mayo Clinic, Mayo Medical School, and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 98:2378-84. 2003
    ....
  91. ncbi Microvascular structural entropy: a novel approach to assess angiogenesis in pituitary tumors
    Sergio Vidal
    Department of Anatomy, Laboratory of Histology, University of Santiago de Compostela, Lugo, Spain
    Endocr Pathol 14:239-47. 2003
    ..Analysis of MSE may provide an independent parameter of tumor behavior, and contributes to a better understanding of the role of microvasculature in pituitary tumor progression...
  92. ncbi Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases
    Thomas A Gaffey
    Mayo Clinic, Rochester, Minnesota 55902, USA
    J Neurosurg 96:352-60. 2002
    ....